Methods and compositions for the inhibition of stat5 in prostate cancer cells
Patent Information
- Authority / Receiving Office
- US · United States
- Current Assignee / Owner
- GEORGETOWN UNIV
- Publication Date
- 2007-01-11
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 
Figure 2
Abstract
Description
RELATED APPLICATION
[0001] This application claims the benefit of priority of U.S. Provisional Application, 60 / 465,014, filed on Apr. 23, 2003, by Marja Nevalainen, entitled “Inhibition of Transcription Factor Stat5 Induces Cell Death of Human Prostate Cancer Cells”. The entire teachings of the referenced Provisional Application are hereby incorporated by reference in their entirety.FUNDING
[0002] Work described herein was funded, in whole or in part, by National Institutes of Health Grant Numbers RO1 CA83813 and RO1 DK52013 and Department of Defense Grant DAMD 17-01-1-0059. The United States government has certain rights in the invention.BACKGROUND OF THE INVENTION
[0003] Currently the only pharmacological strategy for the treatment of prostate cancer is ablation of androgens, either as adjuvant therapy after surgery or as a primary therapy for patients who are deemed unfit for surgery. A central clinical problem in prostate cancer treatment is that residual cancer cells inevitably...